Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group

Ruxolitinib is approved for polycythemia vera (PV) patients after failure to previous cytoreductive therapy, based on durable results observed in phase 3 trials. We report a multicenter retrospective study demonstrating the efficacy and safety of ruxolitinib in real-life setting. Eighty-three patien...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of hematology 2022-06, Vol.101 (6), p.1275-1282
Hauptverfasser:	Pepe, Sara, Rossi, Elena, Trawinska, Malgorzata, Tatarelli, Caterina, Di Veroli, Ambra, Maurillo, Luca, Romano, Atelda, Crescenzi, Sabrina Leonetti, di Toritto, Tommaso Caravita, Tafuri, Agostino, Latagliata, Roberto, Scalzulli, Emilia, Andriani, Alessandro, De Stefano, Valerio, Breccia, Massimo
Format:	Artikel
Sprache:	eng
Schlagworte:	Blood cancer Hematology Humans Hydrogen-Ion Concentration Inhibitor drugs Medicine Medicine & Public Health Nitriles - therapeutic use Oncology Original Article Patients Polycythemia Vera - complications Primary Myelofibrosis - diagnosis Pyrazoles - adverse effects Pyrimidines Retrospective Studies Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Ruxolitinib is approved for polycythemia vera (PV) patients after failure to previous cytoreductive therapy, based on durable results observed in phase 3 trials. We report a multicenter retrospective study demonstrating the efficacy and safety of ruxolitinib in real-life setting. Eighty-three patients were evaluated. Median follow-up was 24.5 months (IQR 14.0–29.3). At a 3-month response assessment, ruxolitinib provided significant benefit in reducing hematocrit (HCT) level ( p
ISSN:	0939-5555 1432-0584
DOI:	10.1007/s00277-022-04815-w